Cidara Therapeutics, Inc. (CDTX)
USD 20.53
(-10.0%)
USD 20.53
(-10.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -22.43 Million | -28.47 Million | -25.23 Million | -54.41 Million | -28.53 Million | -56.7 Million |
| Net Income | -22.93 Million | -29.79 Million | -42.46 Million | -72.11 Million | -41.09 Million | -59.01 Million |
| Depreciation & Amortization | 118 Thousand | 1.22 Million | -1.23 Million | 229 Thousand | 375 Thousand | 523 Thousand |
| Deferred income taxes | - | - | - | - | -411 Thousand | -3.6 Million |
| Stock-based compensation | 3.06 Million | 3.53 Million | 4.01 Million | 4.09 Million | 5.07 Million | 5.71 Million |
| Change in working capital | -3.92 Million | -3.43 Million | 14.43 Million | 13.36 Million | 7.48 Million | -399 Thousand |
| Other non-cash items | 12.16 Million | 1000.00 | 15 Thousand | 21 Thousand | 36 Thousand | 86 Thousand |
| Investing Cash Flow | -505 Thousand | -118 Thousand | -41 Thousand | -186 Thousand | -35 Thousand | 14.3 Million |
| Investments in PPE | -505 Thousand | -118 Thousand | -41 Thousand | -186 Thousand | -35 Thousand | -177 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | -14.54 Million |
| Sales/Maturities of investments | - | - | - | - | - | 29.02 Million |
| Other Investing Activities | - | - | - | - | - | 14.47 Million |
| Financing Cash Flow | 25.98 Million | -951 Thousand | 44.59 Million | 37.27 Million | 14.27 Million | 56.15 Million |
| Debt repayment | - | -2.59 Million | -4.44 Million | -2.96 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | 9 Million | - |
| Common Stock Issuance | 25.98 Million | 2.36 Million | 49.03 Million | 40.22 Million | 14.27 Million | 6.44 Million |
| Other Financing Activities | 25.98 Million | -720 Thousand | 6000.00 | 14 Thousand | 14.27 Million | 49.71 Million |
| Accounts receivables | -10.41 Million | -477 Thousand | 5.81 Million | -11.16 Million | -10 Thousand | 321 Thousand |
| Accounts payables | 8.88 Million | -2.37 Million | -1.09 Million | 6.59 Million | -784 Thousand | -59 Thousand |
| Inventory | -6.09 Million | - | 1.09 Million | -6.59 Million | 10 Thousand | - |
| Other working capital | 3.7 Million | -584 Thousand | 8.61 Million | 24.52 Million | 8.27 Million | -340 Thousand |
| Cash at beginning of period | 32.73 Million | 62.27 Million | 42.94 Million | 60.26 Million | 74.56 Million | 60.81 Million |
| Cash at end of period | 35.77 Million | 32.73 Million | 62.27 Million | 42.94 Million | 60.26 Million | 74.56 Million |
| Capital Expenditure | -505 Thousand | -118 Thousand | -41 Thousand | -186 Thousand | -35 Thousand | -177 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 3.04 Million | -29.54 Million | 19.32 Million | -17.31 Million | -14.29 Million | 13.74 Million |
| Free Cash Flow | -22.93 Million | -28.59 Million | -25.27 Million | -54.59 Million | -28.56 Million | -56.88 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -94.21 Million | -10.32 Million | -5.61 Million | -22.93 Million | -8.17 Million | -12.35 Million |
| Depreciation & Amortization | 57 Thousand | 56 Thousand | 39 Thousand | 118 Thousand | 22 Thousand | -263 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 703 Thousand | 795 Thousand | 830 Thousand | 3.06 Million | 796 Thousand | 795 Thousand |
| Change in working capital | -15.59 Million | 2.61 Million | -8.24 Million | -3.92 Million | 5.45 Million | 14.41 Million |
| Other non-cash items | -1.11 Million | -1.81 Million | 15.51 Million | 12.16 Million | 270 Thousand | 229 Thousand |
| Investing Cash Flow | - | -23 Thousand | -178 Thousand | -505 Thousand | -126 Thousand | -107 Thousand |
| Investments in PPE | - | -23 Thousand | -178 Thousand | -505 Thousand | -126 Thousand | -107 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 239.13 Million | -93 Thousand | 8000.00 | 25.98 Million | - | -261 Thousand |
| Debt repayment | -75 Thousand | -50 Thousand | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | 55 Thousand | -39 Thousand | - | - | 63 Thousand | -261 Thousand |
| Common Stock Issuance | 239.2 Million | -4000.00 | 8000.00 | 25.98 Million | 8.62 Million | -261 Thousand |
| Other Financing Activities | 4000.00 | -39 Thousand | 8000.00 | 25.98 Million | - | - |
| Accounts receivables | 4.65 Million | 8.96 Million | -13.39 Million | -10.41 Million | 2.62 Million | 20.34 Million |
| Accounts payables | -4.73 Million | -4.85 Million | 2.68 Million | 8.88 Million | 3.8 Million | -246 Thousand |
| Inventory | 7.26 Million | -1.17 Million | -3.63 Million | -6.09 Million | -513 Thousand | -1.95 Million |
| Other working capital | -22.78 Million | -331 Thousand | -413 Thousand | 3.7 Million | -468 Thousand | -3.72 Million |
| Cash at beginning of period | 29.01 Million | 35.77 Million | 48.67 Million | 32.73 Million | 50.43 Million | 47.97 Million |
| Cash at end of period | 164.36 Million | 29.01 Million | 35.77 Million | 35.77 Million | 48.67 Million | 50.43 Million |
| Capital Expenditure | - | -23 Thousand | -178 Thousand | -505 Thousand | -126 Thousand | -107 Thousand |
| Effect of forex changes on cash | - | - | - | - | 5.6 Million | - |
| Net cash flow / Change in cash | 135.35 Million | -6.76 Million | -12.89 Million | 3.04 Million | -1.76 Million | 2.45 Million |
| Free Cash Flow | -103.78 Million | -6.66 Million | -12.9 Million | -22.93 Million | -1.76 Million | 2.71 Million |
JOSTS
JAIBALAJI
009420
002547
2364
INSPIRISYS